This inventor holds 1 USPTO granted patent. Top assignee: Atlantos Pharmaceuticals Holding, Inc.. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Michael Essors: Innovator in Pharmaceutical Chemistry
Introduction
Michael Essors is a notable inventor based in Schoenau, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of metalloprotease inhibitors. His work focuses on creating compounds that can effectively target specific enzymes, which are crucial in various biological processes.
Latest Patents
Michael Essors holds a patent for "Heterobicyclic metalloprotease inhibitors." This invention relates to amide group-containing pharmaceutical agents, specifically targeting heterobicyclic metalloprotease inhibitor compounds. The patent details a new class of compounds that exhibit increased potency against MMP-13 and MMP-3, which are important targets in treating various diseases.
Career Highlights
Throughout his career, Michael has been associated with Atlantos Pharmaceuticals Holding, Inc. His work has been instrumental in advancing the understanding and application of metalloprotease inhibitors in medicine. With a focus on innovative solutions, he continues to contribute to the pharmaceutical industry.
Collaborations
Michael has collaborated with notable colleagues, including Torsten Arndt and Ralf Biesinger. These partnerships have enhanced the research and development efforts within his field, leading to more effective pharmaceutical solutions.
Conclusion
Michael Essors is a prominent figure in the realm of pharmaceutical innovation, with a focus on developing potent metalloprotease inhibitors. His contributions are paving the way for advancements in medical treatments.